Clostridioides difficile -induced diarrhoea following dasatinib therapy
Dasatinib, an oral tyrosine kinase inhibitor, is approved for therapy of chronic myeloid leukaemia (CML). Common adverse effects of this therapy include myelosuppression, fluid retention and diarrhoea. However, infections (CDIs) in the context of dasatinib therapy, without a history of antecedent an...
Gespeichert in:
| Veröffentlicht in: | BMJ case reports 2021-01, Vol.14 (1), p.e239394 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | e239394 |
| container_title | BMJ case reports |
| container_volume | 14 |
| creator | Datta, Amlan Kusum Debnath, Partha Chakraborty, Uddalak Chandra, Atanu |
| description | Dasatinib, an oral tyrosine kinase inhibitor, is approved for therapy of chronic myeloid leukaemia (CML). Common adverse effects of this therapy include myelosuppression, fluid retention and diarrhoea. However,
infections (CDIs) in the context of dasatinib therapy, without a history of antecedent antibiotic use, has not been reported previously. We present here a case of a 36-year-old man diagnosed with accelerated phase of CML, who was started on treatment with dasatinib. Two months into therapy, he experienced profuse diarrhoea and abdominal pain. Colonoscopy revealed multiple confluent colonic mucosal ulcerations. Immunoassay study of stool revealed positive
toxin. The patient was started on oral metronidazole, with discontinuation of all other drugs, including dasatinib. He made a complete uneventful recovery following 2 weeks of antibiotic therapy. Chemotherapeutic agents, such as dasatinib, should be considered as possible etiological agents in the pathogenesis of CDI, even in absence of antibiotic use. |
| doi_str_mv | 10.1136/bcr-2020-239394 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7813327</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2512723549</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-9dd321e723b48625e932cc010b923701578dacb012e4eaf92d1cea81864c2cd13</originalsourceid><addsrcrecordid>eNpVkEFLAzEQhYMottSevcmC57WZJLvZXAQpWgXBi4K3kE2ybcp2U5Ot0n9vSmupuUyYefPm8SF0DfgOgJaTWoecYIJzQgUV7AwNgRc85wJ_np_8B2gc4xKnR4FVjF6iAaWsJLjAQzSbtj72wRnnnbExM65pnHatzXLXmY22JrVUCAtvVdb4tvU_rptnRkXVu87VWb-wQa23V-iiUW2040MdoY-nx_fpc_76NnuZPrzmmhHoc2EMJWA5oTWrSlJYQYnWGHAtCOUYCl4ZpWsMxDKrGkEMaKsqqEqmiTZAR-h-77ve1CtrtO36oFq5Dm6lwlZ65eT_SecWcu6_Ja-AUsKTwe3BIPivjY29XPpN6FJmSQogKVnBRFJN9iodfIzBNscLgOUOvkzw5Q6-3MNPGzenwY76P9T0F-JsgR0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2512723549</pqid></control><display><type>article</type><title>Clostridioides difficile -induced diarrhoea following dasatinib therapy</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Datta, Amlan Kusum ; Debnath, Partha ; Chakraborty, Uddalak ; Chandra, Atanu</creator><creatorcontrib>Datta, Amlan Kusum ; Debnath, Partha ; Chakraborty, Uddalak ; Chandra, Atanu</creatorcontrib><description>Dasatinib, an oral tyrosine kinase inhibitor, is approved for therapy of chronic myeloid leukaemia (CML). Common adverse effects of this therapy include myelosuppression, fluid retention and diarrhoea. However,
infections (CDIs) in the context of dasatinib therapy, without a history of antecedent antibiotic use, has not been reported previously. We present here a case of a 36-year-old man diagnosed with accelerated phase of CML, who was started on treatment with dasatinib. Two months into therapy, he experienced profuse diarrhoea and abdominal pain. Colonoscopy revealed multiple confluent colonic mucosal ulcerations. Immunoassay study of stool revealed positive
toxin. The patient was started on oral metronidazole, with discontinuation of all other drugs, including dasatinib. He made a complete uneventful recovery following 2 weeks of antibiotic therapy. Chemotherapeutic agents, such as dasatinib, should be considered as possible etiological agents in the pathogenesis of CDI, even in absence of antibiotic use.</description><identifier>ISSN: 1757-790X</identifier><identifier>EISSN: 1757-790X</identifier><identifier>DOI: 10.1136/bcr-2020-239394</identifier><identifier>PMID: 33462050</identifier><language>eng</language><publisher>England: BMJ Publishing Group LTD</publisher><subject>Adult ; Antibiotics ; Antimicrobial agents ; Antineoplastic Agents - adverse effects ; Case Report ; Case reports ; Clostridioides difficile - isolation & purification ; Clostridium Infections - diagnosis ; Clostridium Infections - etiology ; Clostridium Infections - therapy ; Colonoscopy ; Cytomegalovirus ; Dasatinib - adverse effects ; Diarrhea ; Diarrhea - diagnosis ; Diarrhea - etiology ; Diarrhea - therapy ; Electrolytes ; Erythema ; Gastroenterology ; Humans ; Infections ; Inflammatory bowel disease ; Leukemia ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Male ; Neutrophils ; Patients ; Pleural effusion ; Signal transduction</subject><ispartof>BMJ case reports, 2021-01, Vol.14 (1), p.e239394</ispartof><rights>BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2021 BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-9dd321e723b48625e932cc010b923701578dacb012e4eaf92d1cea81864c2cd13</citedby><cites>FETCH-LOGICAL-c421t-9dd321e723b48625e932cc010b923701578dacb012e4eaf92d1cea81864c2cd13</cites><orcidid>0000-0002-3809-8926 ; 0000-0001-6367-545X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813327/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813327/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33462050$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Datta, Amlan Kusum</creatorcontrib><creatorcontrib>Debnath, Partha</creatorcontrib><creatorcontrib>Chakraborty, Uddalak</creatorcontrib><creatorcontrib>Chandra, Atanu</creatorcontrib><title>Clostridioides difficile -induced diarrhoea following dasatinib therapy</title><title>BMJ case reports</title><addtitle>BMJ Case Rep</addtitle><description>Dasatinib, an oral tyrosine kinase inhibitor, is approved for therapy of chronic myeloid leukaemia (CML). Common adverse effects of this therapy include myelosuppression, fluid retention and diarrhoea. However,
infections (CDIs) in the context of dasatinib therapy, without a history of antecedent antibiotic use, has not been reported previously. We present here a case of a 36-year-old man diagnosed with accelerated phase of CML, who was started on treatment with dasatinib. Two months into therapy, he experienced profuse diarrhoea and abdominal pain. Colonoscopy revealed multiple confluent colonic mucosal ulcerations. Immunoassay study of stool revealed positive
toxin. The patient was started on oral metronidazole, with discontinuation of all other drugs, including dasatinib. He made a complete uneventful recovery following 2 weeks of antibiotic therapy. Chemotherapeutic agents, such as dasatinib, should be considered as possible etiological agents in the pathogenesis of CDI, even in absence of antibiotic use.</description><subject>Adult</subject><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Case Report</subject><subject>Case reports</subject><subject>Clostridioides difficile - isolation & purification</subject><subject>Clostridium Infections - diagnosis</subject><subject>Clostridium Infections - etiology</subject><subject>Clostridium Infections - therapy</subject><subject>Colonoscopy</subject><subject>Cytomegalovirus</subject><subject>Dasatinib - adverse effects</subject><subject>Diarrhea</subject><subject>Diarrhea - diagnosis</subject><subject>Diarrhea - etiology</subject><subject>Diarrhea - therapy</subject><subject>Electrolytes</subject><subject>Erythema</subject><subject>Gastroenterology</subject><subject>Humans</subject><subject>Infections</subject><subject>Inflammatory bowel disease</subject><subject>Leukemia</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Male</subject><subject>Neutrophils</subject><subject>Patients</subject><subject>Pleural effusion</subject><subject>Signal transduction</subject><issn>1757-790X</issn><issn>1757-790X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpVkEFLAzEQhYMottSevcmC57WZJLvZXAQpWgXBi4K3kE2ybcp2U5Ot0n9vSmupuUyYefPm8SF0DfgOgJaTWoecYIJzQgUV7AwNgRc85wJ_np_8B2gc4xKnR4FVjF6iAaWsJLjAQzSbtj72wRnnnbExM65pnHatzXLXmY22JrVUCAtvVdb4tvU_rptnRkXVu87VWb-wQa23V-iiUW2040MdoY-nx_fpc_76NnuZPrzmmhHoc2EMJWA5oTWrSlJYQYnWGHAtCOUYCl4ZpWsMxDKrGkEMaKsqqEqmiTZAR-h-77ve1CtrtO36oFq5Dm6lwlZ65eT_SecWcu6_Ja-AUsKTwe3BIPivjY29XPpN6FJmSQogKVnBRFJN9iodfIzBNscLgOUOvkzw5Q6-3MNPGzenwY76P9T0F-JsgR0</recordid><startdate>20210118</startdate><enddate>20210118</enddate><creator>Datta, Amlan Kusum</creator><creator>Debnath, Partha</creator><creator>Chakraborty, Uddalak</creator><creator>Chandra, Atanu</creator><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3809-8926</orcidid><orcidid>https://orcid.org/0000-0001-6367-545X</orcidid></search><sort><creationdate>20210118</creationdate><title>Clostridioides difficile -induced diarrhoea following dasatinib therapy</title><author>Datta, Amlan Kusum ; Debnath, Partha ; Chakraborty, Uddalak ; Chandra, Atanu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-9dd321e723b48625e932cc010b923701578dacb012e4eaf92d1cea81864c2cd13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Case Report</topic><topic>Case reports</topic><topic>Clostridioides difficile - isolation & purification</topic><topic>Clostridium Infections - diagnosis</topic><topic>Clostridium Infections - etiology</topic><topic>Clostridium Infections - therapy</topic><topic>Colonoscopy</topic><topic>Cytomegalovirus</topic><topic>Dasatinib - adverse effects</topic><topic>Diarrhea</topic><topic>Diarrhea - diagnosis</topic><topic>Diarrhea - etiology</topic><topic>Diarrhea - therapy</topic><topic>Electrolytes</topic><topic>Erythema</topic><topic>Gastroenterology</topic><topic>Humans</topic><topic>Infections</topic><topic>Inflammatory bowel disease</topic><topic>Leukemia</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Male</topic><topic>Neutrophils</topic><topic>Patients</topic><topic>Pleural effusion</topic><topic>Signal transduction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Datta, Amlan Kusum</creatorcontrib><creatorcontrib>Debnath, Partha</creatorcontrib><creatorcontrib>Chakraborty, Uddalak</creatorcontrib><creatorcontrib>Chandra, Atanu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMJ case reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Datta, Amlan Kusum</au><au>Debnath, Partha</au><au>Chakraborty, Uddalak</au><au>Chandra, Atanu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clostridioides difficile -induced diarrhoea following dasatinib therapy</atitle><jtitle>BMJ case reports</jtitle><addtitle>BMJ Case Rep</addtitle><date>2021-01-18</date><risdate>2021</risdate><volume>14</volume><issue>1</issue><spage>e239394</spage><pages>e239394-</pages><issn>1757-790X</issn><eissn>1757-790X</eissn><abstract>Dasatinib, an oral tyrosine kinase inhibitor, is approved for therapy of chronic myeloid leukaemia (CML). Common adverse effects of this therapy include myelosuppression, fluid retention and diarrhoea. However,
infections (CDIs) in the context of dasatinib therapy, without a history of antecedent antibiotic use, has not been reported previously. We present here a case of a 36-year-old man diagnosed with accelerated phase of CML, who was started on treatment with dasatinib. Two months into therapy, he experienced profuse diarrhoea and abdominal pain. Colonoscopy revealed multiple confluent colonic mucosal ulcerations. Immunoassay study of stool revealed positive
toxin. The patient was started on oral metronidazole, with discontinuation of all other drugs, including dasatinib. He made a complete uneventful recovery following 2 weeks of antibiotic therapy. Chemotherapeutic agents, such as dasatinib, should be considered as possible etiological agents in the pathogenesis of CDI, even in absence of antibiotic use.</abstract><cop>England</cop><pub>BMJ Publishing Group LTD</pub><pmid>33462050</pmid><doi>10.1136/bcr-2020-239394</doi><orcidid>https://orcid.org/0000-0002-3809-8926</orcidid><orcidid>https://orcid.org/0000-0001-6367-545X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1757-790X |
| ispartof | BMJ case reports, 2021-01, Vol.14 (1), p.e239394 |
| issn | 1757-790X 1757-790X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7813327 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adult Antibiotics Antimicrobial agents Antineoplastic Agents - adverse effects Case Report Case reports Clostridioides difficile - isolation & purification Clostridium Infections - diagnosis Clostridium Infections - etiology Clostridium Infections - therapy Colonoscopy Cytomegalovirus Dasatinib - adverse effects Diarrhea Diarrhea - diagnosis Diarrhea - etiology Diarrhea - therapy Electrolytes Erythema Gastroenterology Humans Infections Inflammatory bowel disease Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Male Neutrophils Patients Pleural effusion Signal transduction |
| title | Clostridioides difficile -induced diarrhoea following dasatinib therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T03%3A03%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clostridioides%20difficile%20-induced%20diarrhoea%20following%20dasatinib%20therapy&rft.jtitle=BMJ%20case%20reports&rft.au=Datta,%20Amlan%20Kusum&rft.date=2021-01-18&rft.volume=14&rft.issue=1&rft.spage=e239394&rft.pages=e239394-&rft.issn=1757-790X&rft.eissn=1757-790X&rft_id=info:doi/10.1136/bcr-2020-239394&rft_dat=%3Cproquest_pubme%3E2512723549%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2512723549&rft_id=info:pmid/33462050&rfr_iscdi=true |